TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01634256

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(3.0g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fermented turmeric
Description: Fermented turmeric(3.0g/day)
Study: NCT03189290

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: posterior Quadratus Lumborum Block (QLB)
Description: Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterior Quadratus Lumborum Block (QLB)
Description: Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
Study: NCT01622634

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sprint Interval Exercise
Description: Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sprint Interval Exercise
Description: Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher PRO Diet
Description: Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher PRO Diet
Description: Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher CARB Diet
Description: Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher CARB Diet
Description: Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
Study: NCT04585009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3923868
Description: GSK3923868 will be available as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Study: NCT00804687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
Study: NCT04585009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.
Study: NCT00804687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39220675
Description: Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Description: Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
Study: NCT03288246

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: point-of-care viral load test
Description: A point-of-care viral load test returns viral load test results within 90 minutes.
Study: NCT01226290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VizAblate System
Description: VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
Study: NCT04157387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyriax inferior capsular stretching + Manual Therapy
Description: Electro-therapy 10mins Manual therapy : Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Active ROM exercises : 10 reps x 3 sets Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each) Cyriax inferior capsular stretching

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Before starting capsule stretching technique, Analgesic short-wave diathermy may be given for 10 minutes.~Kalternbon grade 1 and 2 Mobilization : Inferior glide (10x3), posterior glide, (10 reps x 3 sets), anterior glide (10 reps x 3 sets), Home plan include :, wall walking exercises, pendulum exercises ,towel stretch exercises, Cross Body Adduction (10reps x 2 sets ,each)
Study: NCT01773421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: FOOD EFFECT STUDY:~Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7820
Description: MTD DETERMINATION FOR BID DOSING SCHEDULE~The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation, the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID.
Study: NCT00808444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A (different lots)
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A (different lots)
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, only for Visit 2 in Singapore

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, only for Visit 2 in Singapore

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral, 2 doses
Study: NCT02327260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video + Motivational interview for CR participation
Description: Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview for medication adherence
Description: The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
Study: NCT04213404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib 400mg, 600mg, or 200mg oral daily, D1-D21, 28 days a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab 400mg ivdrip on D1, 28 days a cycle.
Study: NCT01936389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Study: NCT03526289

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GIP1-42 infusion
Description: 5-hour GIP1-42 infusion (time point 0-300 minutes)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 5-hour infusion of saline (placebo) (time point 0-300 minutes)
Study: NCT01809548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intervention group
Description: solid food will be introduced between week 10 and 12

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Late intervention group
Description: solid food is introduced between 16-18th week of gestation corrected for prematurity
Study: NCT06031077

Intervention type: PROCEDURE
Intervention: cardiac catheterization
Description: An observational, retrospective study will be carried out. Roughly 111 patients were registered at EWMSC and Cardiac Angiograms were done via approached through the left radial access between January 2020 and June 2021 at EWMSC. However since 2021 Cardiac Angiograms were also done via the anatomical snuff box. This study seeks to compare the results of Cardiac Angiograms vs Left Radial Access and the Anatomical Snuff box.
Study: NCT02597855

Intervention type: DRUG
Intervention: Aflibercept
Description: Total 4 times of intravitreal aflibercept injection was performed

Intervention type: DRUG
Intervention: Aflibercept
Description: Total 4 times of intravitreal aflibercept injection was performed

Intervention type: DRUG
Intervention: Indocyanine green angiography (intraveonus indocyanine green dye)
Description: At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.

Intervention type: DRUG
Intervention: Indocyanine green angiography (intraveonus indocyanine green dye)
Description: At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
Study: NCT00746174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 8mg PO daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet PO daily for 16 weeks
Study: NCT01487421

Intervention type: DRUG
Intervention: insulin aspart
Description: Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)

Intervention type: DRUG
Intervention: insulin detemir
Description: Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
Study: NCT04585009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Placebo to match GSK3923868 will be available as capsule containing inhalation powder to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monodose RS01
Description: Participants will receive GSK3923868 and placebo as capsules containing inhalation powder blend to be delivered via Monodose RS01 device.
Study: NCT01373827

Intervention type: DEVICE
Intervention: VASERShape MC1
Description: Use of the VASERShape MC1 device as part of routine practice
Study: NCT01245907

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied relaxation
Description: Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
Study: NCT03785548

Intervention type: OTHER
Intervention: Usage of a mirror
Description: using a mirror during the pelvic examination
Study: NCT01556308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Taking of liquid and top of blisters
Description: the liquid and the top of blisters will be took.
Study: NCT03586700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiao zhong fang granules
Description: Chinese medicine Xiao zhong fang was Professor Sun Chengxiang's experience formula in Massage Department of Dongzhimen Hospital. The function of the formula is to activate blood circulation and dredge collaterals, tonifying kidney and promoting dampness to soothe the liver and nourish tendons.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Short wave infrared radiation
Description: Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short wave infrared radiation
Description: Short waves infrared radiation treatment every other day, ensure 3 times in 7 days, 7 days for a course of treatment, continuously for 4 courses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Xiao zhong fang granules
Description: Made of starch,dextrin and edible pigment from Dongzhimen Hospital of Beijing university of chinese medicine.
Study: NCT02419456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR (Low Dose)
Description: Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2048A IVR (Original Dose)
Description: Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
Study: NCT04000464

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLIPP
Description: Diabetes Prevention program and Comprehensive Lifestyle Improvement Program consisting of low calorie diet, physical activity, sleep optimization and stress management
Study: NCT00558857

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic Substrate Mapping-guided ablation
Description: Radiofrequency ablation
Study: NCT02378571

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication adherence telemonitoring
Description: The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
Study: NCT03265977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H56:IC31
Description: The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03018834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANAKINRA 100 mg/daily subcutaneously
Description: ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
Study: NCT06387771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Tolcapone (Film-coated tablet) 200 mg orally every 8 hours for 7 days
Study: NCT01387022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir, lamivudine and efavirenz
Description: Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir, lamivudine and efavirenz
Description: Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
Study: NCT04470557

Intervention type: DIAGNOSTIC_TEST
Intervention: D-dimer,CBC.ESR,CRP,
Description: Complete blood count (for patients and control subjects): was done on CELL-DYN 3700 (Abbott-Germany) and blood film was stained by leishman staining, the morphology of red blood cells. CRP titre estimation by latix method .ESR erythrocyte sedimentation rate estimation (1:5) by Westerngreen tube method.

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver function tests ,serum ferritin and PCR for COVID-19 .
Description: Serum ferritin was performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, Germany),~• Liver function tests ( aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase) and kidney funcrion were performed for all subjects on Modular P auto analyzer (Roche Diagnostics, Mannheim, G ermany),
Study: NCT00817960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design